Crystal Structure of Bimekizumab Fab Fragment in Complex with IL-17F Provides Molecular Basis for Dual IL-17A and IL-17F Inhibition.

Adams, Ralph; Bunick, Christopher G; Lawson, Alastair D G; Gomez, Braulio; Shaw, Stevan

Adams, Ralph; Bunick, Christopher G; Lawson, Alastair D G; Gomez, Braulio; Shaw, Stevan.

Afiliación

Adams R; UCB Pharma, Slough, United Kingdom. Electronic address: ralph.adams@ucb.com.
Bunick CG; Department of Dermatology, Yale School of Medicine, Yale University, New Haven, Connecticut, USA; Program in Translational Biomedicine, Yale School of Medicine, Yale University, New Haven, Connecticut, USA.
Lawson ADG; UCB Pharma, Slough, United Kingdom.
Gomez B; UCB Pharma, Smyrna, Georgia, USA.
Shaw S; UCB Pharma, Slough, United Kingdom.

J Invest Dermatol ; 2024 Apr 16.

Article en En | MEDLINE | ID: mdl-38631666

Palabras clave

Biochemistry; Drug development; ILs

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Idioma: En Revista: J Invest Dermatol / J. invest. dermatol / Journal of investigative dermatology Año: 2024 Tipo del documento: Article

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google